About the Company
tg therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for b-cell malignancies and autoimmune diseases. currently, the company is developing two therapies targeting hematological malignancies. tg-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the cd20 antigen found on mature b-lymphocytes. tg therapeutics is also developing tgr-1202, an orally available pi3k delta inhibitor. the delta isoform of pi3k is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of b-lymphocytes. both tg-1101 and tgr-1202 are in clinical development for patients with hematologic malignancies. the company also has pre-clinical programs to develop irak4 inhibitors, and anti-pd-l1 and anti-gitr antibodies. tg therapeutics is headquartered in new york city and is traded on nasdaq under the ticker symbol "tgtx".
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $TGTX News
Q4 2023 TG Therapeutics Inc Earnings Call
Jenna Bosco; SVP, Corporate Communications; TG Therapeutics, Inc. Michael Weiss; President & CEO; TG Therapeutics, Inc. Adam Waldman; Chief Commercialization Officer ...
TG Therapeutics Inc TGTX
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
TG Therapeutics Announces Issuance of Additional Patents for BRIUMVI® (ublituximab-xiiy)
NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (TG) today announced the issuance of three additional patents by the United States Patent and Trademark Office ...
TG Therapeutics: Q4 Earnings Snapshot
MORRISVILLE, N.Y. — MORRISVILLE, N.Y. — TG Therapeutics Inc. (TGTX) on Wednesday reported a loss of $14.4 million in its fourth quarter. On a per-share basis, the Morrisville, New York-based ...
TG Therapeutics Announces European Launch of BRIUMVI® (ublituximab-xiiy)
TG Therapeutics, Inc. (NASDAQ: TGTX) (TG Therapeutics) today announced that its ex-US partner, Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the ...
TG Therapeutics, Inc. (TGTX) Q4 2023 Earnings Call Transcript
Greetings, and welcome to the TG Therapeutics Fourth Quarter and Year-End 2023 Financial Results and Business Update Call. At this time, all participants are on a listen-only mode. A brief ...
TG Therapeutics, Inc.: TG Therapeutics Announces Issuance of Additional Patents for BRIUMVI (ublituximab-xiiy)
NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (TG) today announced the issuance of three additional patents by the United States Patent and Trademark Office ...
TG Therapeutics, Inc. (NASDAQ:TGTX) Q4 2023 Earnings Call Transcript
TG Therapeutics, Inc. (NASDAQ:TGTX) Q4 2023 Earnings Call Transcript February 28, 2024 TG Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.1, expectations were $-0.12.
TG Therapeutics Announces Issuance of Additional Patents for BRIUMVI® (ublituximab-xiiy)
TGTX TG Therapeutics Inc TG Therapeutics Announces Issuance of Additional Patents for BRIUMVI® (ublituximab-xiiy) NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ ...
Loading the latest forecasts...